# Filing Detail

Form F-4/A - Registration of securities, foreign private issuers, business combinations: [Amend]
SEC Accession No. 0001213900-25-018981
Filing Date
2025-03-03
Accepted
2025-03-03 06:40:12
Documents
131

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | REGISTRATION STATEMENT | ea0226019-02.htm iXBRL | F-4/A | 23216384
2 | FORM OF PRE-FUNDED WARRANT | ea022601902ex4-1_nlspharma.htm | EX-4.1 | 82933
3 | FORM OF CONTINGENT VALUE RIGHT AGREEMENT, BY AND BETWEEN NLS PHARMACEUTICS LTD. | ea022601902ex4-2_nlspharma.htm | EX-4.2 | 103373
4 | OPINION OF BAKER MCKENZIE SWITZERLAND LTD. REGARDING CERTAIN SWISS TAX MATTERS | ea022601902ex8-1_nlspharma.htm | EX-8.1 | 28261
5 | FEASIBILITY STUDY AGREEMENT, DATED SEPTEMBER 9, 2018, BY AND AMONG KADIMASTEM LT | ea022601902ex10-7_nlspharma.htm | EX-10.7 | 141289
6 | RESEARCH AND LICENSE AGREEMENT, DATED JANUARY 22, 2015, BY AND BETWEEN THE RAMOT | ea022601902ex10-8_nlspharma.htm | EX-10.8 | 341660
7 | COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT, DATED APRIL 29, 2023, BETWEEN | ea022601902ex10-9_nlspharma.htm | EX-10.9 | 121266
8 | AMENDED AND RESTATED RESEARCH AND LICENSE AGREEMENT, DATED MAY 7, 2013, BETWEEN | ea022601902ex10-10_nlspharma.htm | EX-10.10 | 253527
9 | FORM OF INDEMNIFICATION AGREEMENT | ea022601902ex10-11_nlspharma.htm | EX-10.11 | 24370
10 | CONSENT OF PRICEWATERHOUSECOOPERS AG | ea022601902ex23-1_nlspharma.htm | EX-23.1 | 1802
11 | KOST FORER GABBAY KASIERER | ea022601902ex23-3_nlspharma.htm | EX-23.3 | 4246
12 | CONSENT OF PROF. MICHEL REVEL AS DIRECTOR NOMINEE | ea022601902ex99-4_nlspharma.htm | EX-99.4 | 2758
13 | CONSENT OF ERAN IOHAN AS DIRECTOR NOMINEE | ea022601902ex99-5_nlspharma.htm | EX-99.5 | 2942
14 | CONSENT OF LIORA OREN AS DIRECTOR NOMINEE | ea022601902ex99-6_nlspharma.htm | EX-99.6 | 2865
15 | CONSENT OF TAMMY GALILI AS DIRECTOR NOMINEE | ea022601902ex99-7_nlspharma.htm | EX-99.7 | 2800
16 | CONSENT OF RONEN TWITO AS DIRECTOR NOMINEE | ea022601902ex99-8_nlspharma.htm | EX-99.8 | 2868
22 | GRAPHIC | ex23-3_001.jpg | GRAPHIC | 2149
23 | GRAPHIC | ex8-1_001.jpg | GRAPHIC | 7029
24 | GRAPHIC | ex8-1_002.jpg | GRAPHIC | 3767
25 | GRAPHIC | tbarchart_001.jpg | GRAPHIC | 240459
26 | GRAPHIC | tbarchart_010.jpg | GRAPHIC | 161315
27 | GRAPHIC | tcover_001.jpg | GRAPHIC | 1952554
28 | GRAPHIC | tcover_002.jpg | GRAPHIC | 1968254
29 | GRAPHIC | timage_001.jpg | GRAPHIC | 496447
30 | GRAPHIC | timage_002.jpg | GRAPHIC | 108709
31 | GRAPHIC | timage_004.jpg | GRAPHIC | 757600
32 | GRAPHIC | timage_005.jpg | GRAPHIC | 114225
33 | GRAPHIC | timage_006.jpg | GRAPHIC | 469882
34 | GRAPHIC | timage_007.jpg | GRAPHIC | 515097
35 | GRAPHIC | timage_008.jpg | GRAPHIC | 462442
36 | GRAPHIC | timage_009.jpg | GRAPHIC | 379707
37 | GRAPHIC | timage_011.jpg | GRAPHIC | 931655
38 | GRAPHIC | timage_012.jpg | GRAPHIC | 95427
39 | GRAPHIC | timage_013.jpg | GRAPHIC | 78305
40 | GRAPHIC | timage_014.jpg | GRAPHIC | 352499
41 | GRAPHIC | timage_015.jpg | GRAPHIC | 594589
42 | GRAPHIC | timage_016.jpg | GRAPHIC | 322610
43 | GRAPHIC | timage_017.jpg | GRAPHIC | 296596
44 | GRAPHIC | timage_018.jpg | GRAPHIC | 310984
45 | GRAPHIC | timage_019.jpg | GRAPHIC | 412892
46 | GRAPHIC | timage_020.jpg | GRAPHIC | 368677
47 | GRAPHIC | timage_022.jpg | GRAPHIC | 309990
48 | GRAPHIC | timage_023.jpg | GRAPHIC | 441369
49 | GRAPHIC | timage_024.jpg | GRAPHIC | 86503
50 | GRAPHIC | timage_025.jpg | GRAPHIC | 63953
51 | GRAPHIC | timage_026.jpg | GRAPHIC | 80217
52 | GRAPHIC | timage_027.jpg | GRAPHIC | 473560
53 | GRAPHIC | timage_028.jpg | GRAPHIC | 347255
54 | GRAPHIC | tlinechart_001.jpg | GRAPHIC | 255094
55 | GRAPHIC | tlinechart_002.jpg | GRAPHIC | 238760
56 | GRAPHIC | tlinechart_003.jpg | GRAPHIC | 236343
57 | GRAPHIC | tlinechart_004.jpg | GRAPHIC | 343981
58 | GRAPHIC | tmap_001.jpg | GRAPHIC | 1003310
59 | GRAPHIC | tmoorefooter_logo.jpg | GRAPHIC | 28694
60 | GRAPHIC | tmoorefooter_logo1.jpg | GRAPHIC | 28702
61 | GRAPHIC | tmoorefooter_logo2.jpg | GRAPHIC | 28706
62 | GRAPHIC | tmoorefooter_logo3.jpg | GRAPHIC | 28709
63 | GRAPHIC | tnls_logo.jpg | GRAPHIC | 46506
64 | GRAPHIC | tpiechart_001.jpg | GRAPHIC | 258932
65 | GRAPHIC | tproxy_001.jpg | GRAPHIC | 1261476
66 | GRAPHIC | tproxy_002.jpg | GRAPHIC | 1528760
67 | GRAPHIC | tproxy_003.jpg | GRAPHIC | 1205907
68 | GRAPHIC | tsign_moore.jpg | GRAPHIC | 21862
| Complete submission text file | 0001213900-25-018981.txt |  | 80985774

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
17 | XBRL SCHEMA FILE | nlsp-20231231.xsd | EX-101.SCH | 51898
18 | XBRL CALCULATION FILE | nlsp-20231231_cal.xml | EX-101.CAL | 50117
19 | XBRL DEFINITION FILE | nlsp-20231231_def.xml | EX-101.DEF | 268283
20 | XBRL LABEL FILE | nlsp-20231231_lab.xml | EX-101.LAB | 525598
21 | XBRL PRESENTATION FILE | nlsp-20231231_pre.xml | EX-101.PRE | 292583
135 | EXTRACTED XBRL INSTANCE DOCUMENT | ea0226019-02_htm.xml | XML | 1641146

Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: F-4/A | Act: 33 | File No.: 333-284075 | Film No.: 25693690
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)